The text Transcript of Earning call held on 13 August 2026 at 11:30 a.m. (IST)with respect to the unaudited (Standalone & Consolidated) Financial Results of the Company for the quarter ....

Date: 17 August, 2026 The Secretary The Secretary BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1. G Block Dalal Street Bandra -Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai- 400 051 Scrip Code: 544293 Scrip Symbol : SURAKSHA Dear Sir / Ma’am, Reg: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sub: Intimation of availability of text transcript on Analysts / Institutional Investors / Organisations meet- ‘Earnings Call’ Pursuant to Regulation 30(6) and 46(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the text transcript of the Earnings Call held on Thursday, 13 August 2026 at 11:30 a.m. (IST) with respect to the unaudited (standalone and consolidated) financial results of the Company for the quarter ended 30 June 2026 and other business discussions. Please note that the same is also available on the website of the Company at www.surakshanet.com. You are requested to kindly take the same on record. For Suraksha Diagnostic Limited Ritu Mittal Joint Managing Director & CEO DIN: 00165886 Encl: As above Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India E-mail: investors@surakshanet.com I Website: www.surakshanet.com Phone:(033) 6605 9750 “Suraksha Diagnostic Limited Q1 FY '27 Earnings Conference Call” August 13, 2026 MANAGEMENT: DR. SOMNATH CHATTERJEE – CHAIRMAN & JOINT MANAGING DIRECTOR – SURAKSHA DIAGNOSTIC LIMITED MS. RITU MITTAL – JOINT MANAGING DIRECTOR & CHIEF EXECUTIVE OFFICER – SURAKSHA DIAGNOSTIC LIMITED MR. NIREN KAUL – CHIEF SALES OFFICER – SURAKSHA DIAGNOSTIC LIMITED MR. BALGOPAL JHUNJHUNWALA – REGIONAL BUSINESS HEAD – SURAKSHA DIAGNOSTIC LIMITED MODERATOR: MR. SUMEET KHAITAN – MUFG INTIME INDIA PRIVATE LIMITED Page 1 of 17 Suraksha Diagnostic Limited August 13, 2026 Moderator: Ladies and gentlemen, good day and welcome to the Q1 FY '27 Earnings Conference Call of Suraksha Diagnostic Limited. hosted by MUFG Intime. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing ‘*’ then ‘0’ on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Sumeet Khaitan from MUFG Intime. Thank you and over to you, sir. Sumeet Khaitan: Good morning, everyone. I welcome you all to the Earnings Conference Call to discuss Q1 FY '27 results of Suraksha Diagnostic Limited. To discuss the results, we have from the Management, Dr. Somnath Chatterjee, Chairman & Joint Managing Director, Ms. Ritu Mittal, Joint Managing Director & CEO, Mr. Niren Kaul – Chief Sales Officer and Mr. Balgopal Jhunjhunwala – Regional Business Head. So, they will take you through the results and the business performance, post which we will proceed for Q&A session. Before we proceed with the call, a small disclaimer. This conference may contain certain forward-looking statements about the company which are based on the beliefs, opinions and expectations as on date of this call. The actual results may differ materially. These statements are not guarantee of the future performance and involve risk and uncertainty that are difficult to predict. A detailed safe harbor statement is also been given in the company's investor presentation. With this, I would now like to hand over the call to the management for their opening remarks. Thank you and over to you, sir. Somnath Chatterjee: Good morning. I, Dr. Somnath Chatterjee, welcome you all to the Quarter 1 FY '27 Earnings Conference Call of Suraksha Diagnostic. We are indeed pleased to report a very strong start to FY '27 with continued progress across financial performance, clinical capabilities and our strategic initiatives. For Quarter 1 FY '27, Suraksha delivered a year-on-year revenue growth of 21%, with an EBITDA growth of 28% and a remarkable PAT growth of 40%. We believe this performance reflects the strength of our underlying business and the continued excellent execution of our long-term strategy. Suraksha continues to strengthen its position as an integrated diagnostic service provider in Eastern India. Our focus remains on building deeper clinical capabilities and staying ahead of the curve in technology while continuing to improve our accessibility and patient experience. Page 2 of 17 Suraksha Diagnostic Limited August 13, 2026 During the quarter, Suraksha Genomics continued to demonstrate encouraging traction. The vertical recorded a revenue of Rs. 13.7 million, registering a 136% year-on-year growth with five consecutive quarters of sequential growth. While this remains a small base today, we believe it has the potential to become a meaningful pillar of the business as we scale the platform. We continue to build capabilities across prenatal diagnostics, inherited diseases, pharmacogenomics and oncology-focused molecular panels while also working towards areas such as whole genome testing, metagenomics and AI integration. Here we would like to mention that we have just introduced a blood test for Alzheimer test with excellent feedback from the doctors. Also, we have started a project on early detection of Alzheimer disease from plain brain MRI with the help of artificial intelligence. This is done by a team of neurologists and neuroradiologists from Suraksha with the help of CSIR. Our technology initiatives and strategic partnerships are also progressing well, helping us strengthen our clinical capabilities and explore new opportunities in advanced diagnostics, research and technology-led healthcare solutions. We believe these collaborations will continue to complement our in-house capabilities and create meaningful opportunities over the long term. We remain focused on combining clinical expertise, technology and strategic collaboration to build a differentiated diagnostic platform for Eastern India and adjacent geographies. With this, I would like to invite our CEO, Mrs. Ritu Mittal, to provide the financial and operational update for Quarter 1 FY '27. A very good day to you all, and thank you. Ritu Mittal: Thank you Dr. Chatterjee. Good afternoon, everyone, and thank you for joining us today. I am pleased to report that Suraksha has begun FY '27 on a very strong footing. The quarter reflects healthy business momentum and continued execution of our expansion strategy. During Q1, we commissioned one hub and three spoke centers, consistent with our strategy of anchoring clusters and then building density around them. We have carried this momentum into the current quarter as well, adding two hubs and three spoke centers in July and August. Importantly, we have also extended our footprint beyond West Bengal with the commissioning of a hub center in the neighboring state of Jharkhand, while a hub in Tripura will follow shortly. This marks an important step in our journey of building a broader regional presence across Eastern and Northeastern India. As we continue to expand our network, our focus remains on ensuring that the newer centres ramp up efficiently. We remain acutely focused on improving throughput and capacity utilization across recently launched centres, while maintaining disciplined execution of our expansion plan. At the same time, we continue to pursue cost efficiencies by leveraging our centralized procurement and existing infra. This will remain important as we scale the network and progressively improve operating leverage. Page 3 of 17 Suraksha Diagnostic Limited August 13, 2026 I will now take you through the brief overview of our financial performance for the quarter ended 30th June 2026. For Q1, the company reported total income of INR 887 million compare [Showing first 8,000 characters — download PDF for full document]